Cargando…

Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC

INTRODUCTION: Durvalumab after concurrent chemoradiation (CCRT) for NSCLC improves survival, but only in a subset of patients. We investigated the effect of severe radiation-induced lymphopenia (sRIL) on survival in these patients. METHODS: Outcomes after CCRT (2010–2019) or CCRT followed by durvalu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jing, Wang, Xu, Ting, Wu, Lirong, Lopez, Pablo B., Grassberger, Clemens, Ellsworth, Susannah G., Mohan, Radhe, Hobbs, Brian P., Blumenschein, George R., Tu, Janet, Altan, Mehmet, Lee, Percy, Liao, Zhongxing, Lin, Steven H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449658/ https://www.ncbi.nlm.nih.gov/pubmed/36089921 http://dx.doi.org/10.1016/j.jtocrr.2022.100391

Ejemplares similares

Radiation-Induced Lymphopenia Risks of Photon Versus Proton Therapy for Esophageal Cancer Patients
por: Ebrahimi, Saba, et al.
Publicado: (2021)

Impact of Lymphopenia Recovery After Chemoradiotherapy on Durvalumab Consolidation Therapy in Stage III NSCLC
por: Kuge, Tomoki, et al.
Publicado: (2023)

Neural network based ensemble model to predict radiation induced lymphopenia after concurrent chemo-radiotherapy for non-small cell lung cancer from two institutions
por: Kim, Yejin, et al.
Publicado: (2023)

Lymphocyte Depletion Rate as a Biomarker of Radiation Dose to Circulating Lymphocytes During Fractionated Partial-Body Radiation Therapy
por: Ellsworth, Susannah G., et al.
Publicado: (2022)

Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAP
por: Faehling, Martin, et al.
Publicado: (2020)

Longitudinal changes of blood parameters and weight in inoperable stage III NSCLC patients treated with concurrent chemoradiotherapy followed by maintenance treatment with durvalumab
por: Guggenberger, J., et al.
Publicado: (2022)

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC
por: Gray, Jhanelle E., et al.
Publicado: (2019)

Concurrent Chemoradiation With or Without Durvalumab in Elderly Patients With Unresectable Stage III NSCLC: Safety and Efficacy
por: Lau, Sally C.M., et al.
Publicado: (2021)

Field size effects on the risk and severity of treatment-induced lymphopenia in patients undergoing radiation therapy for solid tumors
por: Ellsworth, Susannah G.
Publicado: (2018)

Implementation of durvalumab maintenance treatment after concurrent chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC)—a German radiation oncology survey
por: Käsmann, Lukas, et al.
Publicado: (2020)

Effect of durvalumab on local control after concurrent chemoradiotherapy for locally advanced non‐small cell lung cancer in comparison with chemoradiotherapy alone
por: Abe, Takanori, et al.
Publicado: (2020)

Lymphopenia in Esophageal Squamous Cell Carcinoma: Relationship to Malnutrition, Various Disease Parameters, and Response to Concurrent Chemoradiotherapy
por: Zhou, Xi‐Lei, et al.
Publicado: (2019)

Durvalumab in NSCLC: latest evidence and clinical potential
por: Muñoz-Unceta, Nerea, et al.
Publicado: (2018)

Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
por: Fitzpatrick, Orla, et al.
Publicado: (2021)

Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients
por: Taugner, Julian, et al.
Publicado: (2021)

Dosimetric analysis of lymphopenia during chemoradiotherapy for esophageal cancer
por: Newman, Neil B., et al.
Publicado: (2020)

Comparison of 2-Weekly Versus 4-Weekly Durvalumab Consolidation for Locally Advanced NSCLC Treated With Chemoradiotherapy: A Brief Report
por: Denault, Marie-Hélène, et al.
Publicado: (2022)

Real‐world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non‐small cell lung cancer
por: Huang, Yiqing, et al.
Publicado: (2022)

Successful Treatment with Definitive Concurrent Chemoradiotherapy Followed by Durvalumab Maintenance Therapy in a Patient with Tracheal Adenoid Cystic Carcinoma
por: Mikami, Erika, et al.
Publicado: (2023)

Metabolic patterns on [(18)F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment
por: Holzgreve, Adrien, et al.
Publicado: (2023)

Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non‐small cell lung cancer prior to the approval of durvalumab
por: Fukui, Tomoya, et al.
Publicado: (2020)

Radiation-Associated Lymphopenia and Outcomes of Patients with Unresectable Hepatocellular Carcinoma Treated with Radiotherapy
por: De, Brian, et al.
Publicado: (2021)

Hypofractionated concurrent chemoradiotherapy related lymphopenia and its association with survival in locally advanced non-small cell lung cancer patients
por: Liu, FangJie, et al.
Publicado: (2022)

Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer
por: Mayahara, Hiroshi, et al.
Publicado: (2022)

Destroyed lung due to sustained inflammation after chemoradiotherapy followed by durvalumab
por: Taima, Kageaki, et al.
Publicado: (2020)

Coronary artery calcium score on standard of care oncologic CT scans for the prediction of adverse cardiovascular events in patients with non-small cell lung cancer treated with concurrent chemoradiotherapy
por: Koutroumpakis, Efstratios, et al.
Publicado: (2022)

Chemo-radiotherapy plus durvalumab for loco-regional relapse of resected NSCLC
por: Borghetti, Paolo, et al.
Publicado: (2022)

CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study
por: Mayadev, Jyoti, et al.
Publicado: (2020)

Incidence and dose-volume relationship of radiation pneumonitis after concurrent chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer
por: Saito, Satoshi, et al.
Publicado: (2020)

Clinicopathological analysis of a superior sulcus tumor treated by salvage surgery after concurrent definitive chemoradiotherapy followed by durvalumab: A case report
por: Funaki, Soichiro, et al.
Publicado: (2022)

Predictors of lung injury during durvalumab maintenance therapy following concurrent chemoradiotherapy in unresectable locally advanced non‐small cell lung carcinoma
por: Hirama, Nobuyuki, et al.
Publicado: (2023)

Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study)
por: Yamada, Tadaaki, et al.
Publicado: (2020)

Dosimetric Modeling of Lymphopenia in Patients With Metastatic Cancer Receiving Palliative Radiation and PD-1 Immune Checkpoint Inhibitors
por: Qian, Jack M., et al.
Publicado: (2021)

Pneumonitis During Durvalumab Consolidation Therapy Affects Survival in Stage III NSCLC
por: Kinehara, Yuhei, et al.
Publicado: (2023)

Severe radiation-induced lymphopenia during concurrent chemoradiotherapy for stage III non-small cell lung cancer: external validation of two prediction models
por: van Rossum, Peter S. N., et al.
Publicado: (2023)

Pretreatment SUV(max) value to predict outcome in patients with stage III NSCLC receiving concurrent chemoradiotherapy
por: Yaprak, Gokhan, et al.
Publicado: (2019)

Association between treatment-related lymphopenia and survival in glioblastoma patients following postoperative chemoradiotherapy
por: Mapelli, Roberto, et al.
Publicado: (2021)

Pericardial irradiation dose may be strongly associated with grade 4 lymphopenia and affect prognosis in patients with locally advanced esophageal cancer receiving definitive concurrent chemoradiotherapy
por: Chen, Xianyan, et al.
Publicado: (2023)

Association Between the Early Discontinuation of Durvalumab and Poor Survival in Patients With Stage III NSCLC
por: Shaverdian, Narek, et al.
Publicado: (2021)

Lymphopenia, Lymphopenia-Induced Proliferation, and Autoimmunity
por: Sheu, Ting-Ting, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5svs3h43naj4ahq3gtm49cos71